The purpose of the study was to evaluate the effect of delayed granulocyte colony-stimulating factor (G-CSF) use on hematopoietic recovery post-autologous peripheral blood progenitor cell (PBPC) transplantation. Patients were randomized to begin G-CSF on day +1 or day +7 post transplantation. Thirty-seven patients with lymphoma or myeloma undergoing high-dose therapy and autologous PBPC rescue were randomized to daily subcutaneous G-CSF beginning on day +1 or day +7 post-transplant. Patients р70 kg received 300 g/day and Ͼ70 kg 480 g/day. All patients were reinfused with PBPCs with a CD34
costs. For patients with an adequately mobilized PBPC graft, the initiation of G-CSF can be delayed until day +7 post-PBPC reinfusion. Keywords: G-CSF; randomized trial; autologous transplantation; peripheral blood progenitor cells High-dose therapy followed by hematopoietic stem cell rescue is increasingly utilized in the treatment of both hematologic and nonhematologic malignancies. Such treatment is associated with a regimen-related mortality of 5-10%, mainly due to infectious complications during the time of profound neutropenia (ANC Ͻ0.5 × 10 9 /l). 1 The availability of myeloid growth factors has resulted in their widespread use both pretransplantation as part of stem cell priming regimens and post-transplantation. The goal post stem cell reinfusion is to shorten the period of neutropenia, thereby reducing the number of febrile neutropenic days, infectious episodes, antibiotic therapy days and days in hospital, as well as the cost of transplantation and ultimately, it is hoped, the incidence of treatment-related mortality.
Several studies have addressed these issues. It appears clear that the use of myeloid growth factors following autologous (unprimed) bone marrow transplantation (ABMT) accelerates neutrophil recovery compared to no growth factor use. [2] [3] [4] [5] [6] [7] [8] [9] Similarly, neutrophil engraftment is accelerated in the setting of autologous peripheral blood progenitor cell (PBPC) transplantation in most, but not all, studies. [10] [11] [12] [13] Furthermore, the quality of the mobilized PBPC product is likely to have an independent impact on time to engraftment whether or not growth factors are used.
14 Both the optimum dose and time of initiation of growth factor use post high-dose therapy and stem cell rescue remain to be determined.
The main effect of granulocyte colony-stimulating factor (G-CSF) on stem cell grafts is to stimulate the formation of mature neutrophilic granulocytes. 15 During the immediate post-transplant period, G-CSF responsive, late-committed neutrophilic progenitors have not yet been formed, and the administration of G-CSF prior to such a time may have little effect. This would safely permit the delayed initiation of G-CSF post-transplantation with benefits including cost savings and less discomfort and inconvenience to the patients. We report the results of a randomized study of G-CSF use post autologous PBPC transplantation in patients with hematologic malignancies, in which patients were randomized to G-CSF beginning on either day +1 or day +7 post-PBPC reinfusion.
Patients and methods

Patients
During the period of November 1994 to May 1996, 37 consecutive patients at our institution undergoing autologous PBPC transplantation in whom a CD34
+ cell count of Ͼ2.0 × 10 6 /kg was collected were randomized to recombinant human G-CSF (Neupogen; Amgen, Mississauga, Canada) beginning on either day +1 or day +7 post-transplantation. Study patients had a diagnosis of non-Hodgkin's lymphoma, Hodgkin's lymphoma or multiple myeloma, were between the ages of 19 and 61 years and had an Eastern Oncology Cooperative Group (ECOG) performance status of 0 or 1. Exclusion criteria were congestive heart failure (New York Heart Association class III or IV), active chronic hepatitis, pregnancy or lactation and human immunodeficiency virus (HIV) infection. Informed consent was obtained from all patients.
Peripheral blood stem cell harvesting, CD34
+ cell count determination and cryopreservation PBPCs were mobilized using chemotherapy followed by 10 days of subcutaneous G-CSF injections. Chemotherapy regimens used were DHAP, miniBEAM or cyclophosphamide (4.5 g/m 2 ), based on the patient's underlying illness and response to previous therapies. For priming, G-CSF was administered for 10 days subcutaneously at 300 g daily for patients р70 kg and 480 g daily for patients Ͼ70 kg, with the first dose being given 1 day following the completion of chemotherapy. Apheresis was performed using a continuous flow cell separator (COBE, Boulder, CO, USA) over 2 consecutive days, the first day of collection being the last (10th) day of G-CSF injections. Double-lumen central venous catheters or peripheral veins were used for apheresis procedures. The total volume of blood processed per collection was 10 liters. PBPCs were cryopreserved in the vapor phase of liquid nitrogen in 5% dimethyl sulfoxide using a controlled-rate freezer. CD34 + counts were performed prior to cryopreservation using fluorochrome labeled anti-CD34 + antibodies after adjusting quadrants with matched isotype controls. Actual body weight was used to determine total CD34 + cell count per recipient weight.
Conditioning regimen, supportive care and G-CSF use
High-dose therapy and supportive care were administered when possible in the out-patient setting, with patients being admitted for specific complications as per our out-patient blood and marrow transplant programme protocol. 16 Conditioning regimens used were disease-specific: CBV (etoposide 2400 mg/m PBPCs were thawed in a 37°C waterbath at the bedside and rapidly reinfused on day 0, with G-CSF administration beginning on day +1 or day +7, according to randomization.
All patients received pneumocystis pneumonia prophylaxis with trimethoprim-sulfamethoxazole (1600 mg trimethoprim) twice weekly and herpes simplex virus prophylaxis with acyclovir 800 mg p.o. three times daily. No other antibiotic, antiviral or antifungal prophylaxis was routinuely used. Febrile neutropenia was diagnosed when the temperature was Ͼ38°C with an ANC Ͻ0.5 × 10 9 /l. Patients could continue therapy in the out-patient setting if declared clinically stable. Appropriate cultures were drawn and empiric therapy with intravenous broad-spectrum antibiotics was initiated. Modifications to therapy were made according to positive microbiologic culture and sensitivity results. Vancomycin was utilized for suspected central venous catheter infections or documented bacteremias with organisms susceptible only to vancomycin. The empiric use of vancomycin was discontinued at our institution 3 months into this study period. Amphotericin B (0.5 mg/kg/day) was used empirically during the neutropenic period following the development of a new fever after initial defervesence on broad-spectrum antibiotics or after 5 days of continued fever, and for the treatment of known fungal infections (1 mg/kg/day). Intravenous antibiotics were usually discontinued on the first day of an ANC у0.5 × 10 9 /l if the patient was afebrile.
All blood products administered were irradiated, and platelets were of random donor origin. Patients were transfused as per standing orders and as necessary clinically with 2 units of packed red blood cells (PRBC) if the hemoglobin was Ͻ90 g/l and 5 units of random donor platelets if the platelet count was Ͻ20 × 10 9 /l, or Ͻ30 × 10 9 /l if the patient was febrile. Daily blood counts were performed from initiation of high-dose therapy until hospital discharge.
G-CSF injections were discontinued on the first day of an ANC у0.5 × 10 9 /l. Patients were discharged from the programme when their ANC was у0.5 × 10 9 /l and they were clinically well. Other than the change in use of vancomycin, supportive care and discharge practices were consistent during the study period.
Statistical analysis
All results were analyzed on an intention to treat basis. The objectives of the study were to compare time to neutrophil and platelet recovery, febrile days, days of intravenous antibiotics, days from stem cell product reinfusion until discharge and number of PRBC transfusions between the two groups. A sample size of 34 patients was required to have an 80% power to detect a 3-day difference in days to neutrophil engraftment, which was felt to be clinically significant.
The log rank test was used to compare time-dependent variables, and quantitative data were compared using the Mann-Whitney U test. The number of platelet transfusions 967 was not used as an outcome measure because many patients returned to remote geographical areas at discharge where transfusion practices varied.
For all comparisons, P values were two-sided and a P value less than 0.05 was considered statistically significant. Analysis was conducted with the Prism Statistical software package (GraphPad Software, San Diego, CA, USA).
Results
Patients, PBPC collections and preparative regimens
A total of 37 patients were entered into the study, 16 randomized to the day +1 G-CSF arm and 21 to the day +7 G-CSF arm. Baseline characteristics of age, sex and diagnosis are summarized in Table 1 . Age and sex distributions were comparable between groups.
The median number of CD34 + cells per recipient weight was 5.87 × 10 6 /kg in the day +1 group and 7.70 × 10 9 /kg in the day +7 group (P = 0.70, Table 2 ). 
Days to neutrophil and platelet recovery and G-CSF usage
Data on hematopoietic recovery and G-CSF use are shown in Table 2 . The median time to neutrophil recovery was 9 days in the day +1 group and 10 days in the day +7 group, a difference which was not statistically significant (P = 0.68) (Figure 1 ). Similarly, platelet recovery was not significantly different between the groups, being 10 days in the day +1 arm and 11 days in the day +7 arm (P = 0.83). G-CSF was administered for a median of 3 days in the day +7 group compared to 8 days in the day +1 group (P Ͻ 0.0001).
Febrile neutropenic days, intravenous antibiotic days and PRBC transfusions
The median number of febrile neutropenic days was 4 in the day +1 group and 6 in the day +7 group (P = 0.70). The median number of intravenous antibiotic days was 7 in the day +1 arm and 8 in the day +7 arm (P = 0.54). Similarly, the number of PRBC transfusions was not different between the two groups (P = 0.82).
Number of days in hospital
The median length of stay from PBPC reinfusion until discharge was 11 days in both groups.
Discussion
As indications for high-dose therapy and hematopoietic stem cell rescue continue to expand and age restrictions are softened, it has become increasingly important to optimize all aspects of care, including the components of supportive care, in order to meet the increased demands with available resources. The major morbidity and mortality of such treatments occurs as a result of the infectious complications associated with the 7-14 day period of profound neutropenia. The duration of neutropenia may be shorter but not eliminated with the shift from bone marrow to primed PBPCs as the rescue product. 17 The use of myeloid growth factors has the potential to enhance neutrophil engraftment, and several studies have addressed this issue. The use of growth factors post-ABMT using resting (unprimed) bone marrow has been evaluated in several studies. A significant decrease in days to neutrophil engraftment has been found compared to historical controls 3, 4, 9 and in randomized, placebo controlled trials. [5] [6] [7] [8] 18 In some of these studies, an accompanying reduction in the number of febrile days, the number of infections and days in hospital was observed. 3, 5, 6, 8, 18 Studies of myeloid growth factor use following PBPC rescue have yielded varying results. A decreased time to neutrophil engraftment was shown in a randomized study using a G-CSF and GM-CSF combination beginning on day +1 post-combined marrow and PBPC infusion compared with no growth factor use. 18 A randomized study using G-CSF beginning on day +1 post stem cell infusion (about half of patients received marrow and PBPC, the others PBPC alone) compared with no growth factor use demonstrated statistically significant acceleration of neutrophil engraftment.
11 Accelerated neutrophil engraftment was demonstrated in a study using low-dose G-CSF at 50 g/m 2 /day post-PBPC infusion compared with matched controls receiving no G-CSF. 12 McQuaker et al 13 have recently confirmed this benefit in a randomized, placebo controlled trial, with an associated reduction in both hospital stay and in transplant-related costs. However, this observation has not been universal, as Cortelazzo et al 19 found no benefit of G-CSF administration post-transplant in patients undergoing PBPC transplantation. These patients, however, received high doses of CD34 + cells, with a median of 14 × 10 6 /kg (range 8-64), well above the threshold of 2 × 10 6 /kg below which the risk of delayed engraftment has been reported to increase.
The objective of our study was to compare early vs delayed initiation of G-CSF post-autologous PBPC transplantation. We hypothesized that during the period of absolute agranulocytosis post-stem cell reinfusion, G-CSF was unlikely to have a significant effect, as its main mechanism of action is to enhance the differentiation and proliferation of mature granulocytic precursors. 15 Vey et al 9 compared the initiation of G-CSF on day +6 and day +1 with historical controls receiving no growth factor post-BM infusion, and found no difference in neutrophil recovery was found between the day +1 and day +6 groups, however delayed recovery in the group without G-CSF. 9 This was confirmed in a prospective randomized trial by Faucher et al 20 of day +1 vs day +6 G-CSF post PBPC rescue, in which there was no difference in time to neutrophil or platelet recovery between the two arms. Our study confirms these results with day +1 vs day 7 initiation of G-CSF.
We felt that a clinically significant difference worth detecting in days to neutrophil engraftment was a delay of 3 days when initiating G-CSF therapy on day +7 vs on day +1, and accordingly, the power of this study was set to detect a 3-day difference. Due to the small amount of variation in time to ANC recovery between patients, the study, in fact, had a Ͼ90% power to detect a 2-day difference in time to ANC recovery. Our patients all had hematological malignancies, and received a minimum CD34 + cell dose of 2 × 10 6 /kg recipient weight. Our results demonstrate that neutrophil engraftment is not significantly delayed when G-CSF is initiated on day +7 compared to day +1 post-PBPC infusion in this setting. There was also no difference in the number of febrile days, number of intravenous antibiotic days, number of transfusions or number of days in hospital post-re-infusion.
This approach resulted in the reduction of the number of G-CSF doses administered from a median of eight in the day +1 arm to three doses in the day +7 arm, with an obvious positive impact on cost savings.
We conclude that the initiation of G-CSF on day +7 posthigh-dose therapy and PBPC rescue does not result in a clinically significant delay in neutrophil engraftment compared with its initiation on day +1. Similarly, the number of febrile days, antibiotic days, PRBC transfusions and days in hospital post-re-infusion are not affected. For programmes with limited budgets, the allocation of the additional doses of G-CSF saved by starting on day +7 to ensure adequate numbers of PBPC are collected may be a better use of resources. The precise role of G-CSF in patients with optimally mobilized PBPC grafts remains to be determined.
